The global coagulation factor IX market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Factor IX is a class of protein which is naturally formed in the body. It supports the blood to form clots in order to stop bleeding. This protein circulates in the bloodstream in an inactive form until an injury that damages blood vessels take place. As a result of the injury, coagulation factor IX is activated by another coagulation factor called factor XIa. Injections of factor IX are used to treat hemophilia B, which is sometimes also referred to as Christmas disease. Physicians generally recommend treatment agents, such as coagulation factor IX, for either episodic or prophylactic care. Episodic treatment is used to stop a patient’s bleeding episodes, whereas, prophylactic care is used to prevent bleeding episodes from occurring. By transforming severe hemophilia (factor VIII or IX less than 1%) into a clinically milder version of the disease, clotting factor concentrate prophylaxis aims to preserve joint function.
The market growth is majorly attributable to the unmet medical need for treating hemophilia. Adding to this, the increase in the number of hemophilic patients around the globe also raises concern, thereby spurring the demand for coagulation factor IX. Moreover, the market is expected to expand as the rate of hemophilia diagnosis rises and the usage of prophylactic treatment for hemophilia increases. However, the high cost of recombinant products, serious side effects associated with plasma-derived therapies, and strict regulatory regulations are all restraining the growth of the global coagulation factor IX market.
(Get 15% Discount on Buying this Report)
Get Sample Copy of Coagulation Factor IX Market at:
https://orionmarketreports.com/request-sample/?id=94037&submit=Request+Sample%0D%0A
Market Coverage
The market number available for – 2021-2028
Base year- 2021
Forecast period- 2022-2028
Segment Covered-
By Type
By Application
Regions covered-
North America
Europe
Asia-Pacific
Rest of the World
Top Major Key Players:
Pfizer Inc., Baxter International Inc., and Novo Nordisk A/S, among others.
Key questions addressed by the report
What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How COVID-19 impacted the market?
Deviation from the pre-COVID-19 forecast
Most affected region and segment
Who is the leader in the market?
How are players addressing challenges to sustain growth?
Where is the investment opportunity?
A full report of Coagulation Factor IX Market is available at:
https://orionmarketreports.com/global-coagulation-factor-ix-market/94037/
Global Coagulation Factor IX Market Report by Segment
By Application
Recombinant
Plasma Derived
By Application
Adults
Kids
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
